Amundi 13F: Adds $2.9B to AstraZeneca (AZN) Stake
Amundi has significantly boosted its position in AstraZeneca, reflecting a strong commitment to the healthcare sector.
Reviewed by automated data checks against the source filing. How we make and check alerts
Amundi added 15,375,659 shares to its stake in AstraZeneca PLC ($AZN), a 146574.44% increase, according to a 13F filing with the SEC dated May 18, 2026. It reported 15,386,149 shares worth $2.92 billion at the end of the quarter.
Since the filing, $AZN is up 1.8% after 1 week, down 3.3% after 1 month and down 10.1% to date (from the $183.92 close on May 18, 2026).
AZN
AstraZeneca PLC
Key Points
- Amundi boosted its stake in AstraZeneca PLC (NYSE: AZN) by 15.4 million shares, bringing its total to about 15.4 million shares valued at approximately $2.92 billion as of May 18, 2026.
- Amundi held 15,386,149 $AZN shares at quarter end, up 146574.44% from the prior quarter.
- This increase represents a 146,574% change from the previous holding of just 10,490 shares, showcasing a major shift in Amundi's investment strategy.
- AstraZeneca currently has a P/E ratio of 25.16 and is positioned well above its 52-week low of $145.80, indicating strong market performance.
Get $AZN trade alerts by text
We text you when insiders, Congress or big funds trade $AZN. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated AstraZeneca PLC alert may contain errors. Disclosures
Amundi's Major Stake Increase
Amundi has boosted its stake in AstraZeneca PLC (NYSE: AZN) by 15.4 million shares, raising its total holdings to about 15.4 million shares valued at approximately $2.92 billion as of May 18, 2026. This is a dramatic increase from its previous holding of just 10,490 shares.
Institutional Activity
In recent months, other funds have also adjusted their positions in AstraZeneca. For example, Intech Investment Management initiated a new position with 108,700 shares, while Tidal Investments significantly increased its stake by over 878% during the latest quarter. These moves highlight a growing interest in AstraZeneca among institutional investors.
How AstraZeneca PLC Stock Has Traded
AstraZeneca shares recently traded at $189.62, well above its 52-week low of $145.80, indicating strong investor confidence. The stock has shown resilience with a market capitalization of around $260.7 billion and a P/E ratio of 25.16, reflecting solid earnings potential.
Analysts Set New Price Targets
On August 24, 2026, CICC initiated coverage on AstraZeneca with an "Outperform" rating and a price target of $198. The consensus among analysts is strong, with a recommendation key of "strong buy" and a mean target price of $212.17 based on 11 analyst opinions.
What AstraZeneca PLC Does
AstraZeneca is a biopharmaceutical company based in Cambridge, UK, focusing on the development and commercialization of prescription medicines across various therapeutic areas, including oncology and cardiovascular health. Amundi's increased investment signals confidence in AstraZeneca's growth potential.
What's Ahead for AstraZeneca PLC
AstraZeneca is scheduled to announce its next earnings on October 30, 2026. The recent 13F filing from Amundi reflects its holdings as of the reporting period and may not represent the investor's current position. Investors should keep an eye on AstraZeneca's upcoming earnings and any further institutional filings for additional insights into market trends.
Related Filing Alerts
Source: Amundi's 13F filing on $AZN (May 18, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Find the original filing: Amundi 13F filings on SEC EDGAR. Written by software, not financial advice. How we make alerts